valentDepartment of Hematology, Internal Medicine I, Medical University of Vienna

M.D.: Medical University of Vienna

Research Interests:
• Basophils and Mast Cells
• Allergy and Mastocytosis
• Leukemias and Myeloproliferative Neoplasms
• Neoplastic Stem Cells
• Targeted Drug Therapies

Peter Valent is Professor, Scientific Director of the Ludwig Boltzmann Cluster Oncology and Head of a Research group at the Department of Internal Medicine I at the Medical University of Vienna, Austria. He coordinates the European Competence Network on Mastocytosis (ECNM), the CML and  MDS Platform of the Austrian Society for Hematology and Oncology, runs a Center of Excellence of the MDS Foundation, a Center of Excellence of the ECNM, and has organized a number of Conferences on Diagnostic Criteria and Diagnostic Standards in Vienna in the past 10 years. Special focus in research are the identification of novel markers and targets and the development of disease-related criteria and of targeted drug therapies in myeloid neoplasms. Professor Valent is member in diverse Medical Societies including the American Society of Hematology (ASH), and serves on various editorial boards and as a reviewer in most top hematology journals. He published more than 400 peer-reviewed articles and numerous review articles in his areas of expertise, lectured widely in Europe, North America, and Japan, and received numerous scientific awards. 

Proposed PhD research projects:
1) Identification and validation of BTK as a drug Target in BA and MC    
2) Cytokine-control of IgE-dependent activation of BA and MC

Selected publications:

  1. Krauth, M. T., I. Mirkina, H. Herrmann, C. Baumgartner, M. Kneidinger, and P. Valent. 2009. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 39: 1711-1720. PMID: 19860818.
  2. Hadzijusufovic, E., B. Peter, K. V. Gleixner, K. Schuch, W. F. Pickl, T. Thaiwong, V. Yuzbasiyan-Gurkan, I. Mirkina, M. Willmann, and P. Valent. 2010. H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol. 38: 896-907. PMID: 20570632
  3. Valent, P., S. Cerny-Reiterer, H. Herrmann, I. Mirkina, T. I. George, K. Sotlar, W. R. Sperr, and H. P. Horny. 2010. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol. 23: 369-378. PMID: 21112036
  4. Akin, C., P. Valent, and D. D. Metcalfe. 2010. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol. 126: 1099-1104 e1094. PMID: 21035176
  5. Kneidinger, M., U. Schmidt, U. Rix, K. V. Gleixner, A. Vales, C. Baumgartner, C. Lupinek, M. Weghofer, K. L. Bennett, H. Herrmann, A. Schebesta, W. R. Thomas, S. Vrtala, R. Valenta, F. Y. Lee, W. Ellmeier, G. Superti-Furga, and P. Valent. 2008. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. PMID: 18180381

Other Publications extlink